Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (3843)	2/18/1998 8:12:00 PM
From: Oliver & Co	Read Replies (1) \| Respond to of 6136

"Renal Effects of HIV Protease Inhibitor Indinavir Investigated" Reuters Health Information Services (02/17/98) ÿÿÿÿ In the February issue of Antimicrobial Agents and Chemotherapy, Dr. Kuang C. Yeh of Merck Research Laboratories and colleagues report that the protease inhibitor indinavir should be taken with water to lower the risk of nephrolithiasis.ÿ The researchers tested 28 healthy male volunteers, monitoring plasma and urine concentrations of indinavir.ÿ According to the results, indinavir concentrations increased greater than proportionally to the dose, suggesting nonlinear pharmokinetics.ÿ The Merck group also investigated the effects of dietary intake on indinavir pharmokinetics and found that high-fat meals may result in some precipitation of the drug.